Editas Medicine (EDIT) EBITDA (2015 - 2025)
Editas Medicine (EDIT) reported EBITDA of -$24.5 million for Q3 2025, up 62.62% year-over-year from -$15.1 million in Q3 2024, and up 52.37% on a QoQ basis from -$51.5 million in Q2 2025.
Editas Medicine (EDIT) has 11 years of EBITDA data on file, last reported at -$24.5 million in Q3 2025.
- Quarterly EBITDA rose 62.62% year-over-year to -$24.5 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$198.8 million (up 12.99% YoY) and the FY2024 annual result came in at -$251.2 million, down 48.45% from the prior year.
- EBITDA climbed to -$24.5 million in Q3 2025 per EDIT's latest filing, from -$51.5 million in the prior quarter.
- Across five years, EBITDA topped out at -$24.0 million in Q4 2023 and bottomed at -$76.2 million in Q1 2025.
- The 5-year median for EBITDA is -$51.5 million (2025), against an average of -$52.2 million.
- The widest annual swing landed in 2021, when EBITDA plunged 536.68%; it then jumped 62.62% in 2025.
- Tracing EDIT's EBITDA over 5 years: stood at -$41.6 million in 2021, then plunged by 52.48% to -$63.4 million in 2022, then surged by 62.23% to -$24.0 million in 2023, then slumped by 94.45% to -$46.6 million in 2024, then surged by 47.31% to -$24.5 million in 2025.
- Per Business Quant, the three latest EDIT EBITDA figures stand at -$24.5 million (Q3 2025), -$51.5 million (Q2 2025), and -$76.2 million (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -24.55 Mn |
| Jun 30, 2025 | -51.54 Mn |
| Mar 31, 2025 | -76.16 Mn |
| Dec 31, 2024 | -46.59 Mn |
| Sep 30, 2024 | -65.67 Mn |
| Jun 30, 2024 | -71.90 Mn |
| Mar 31, 2024 | -66.99 Mn |
| Dec 31, 2023 | -23.96 Mn |
| Sep 30, 2023 | -50.16 Mn |
| Jun 30, 2023 | -44.09 Mn |
| Mar 31, 2023 | -50.96 Mn |
| Dec 31, 2022 | -63.45 Mn |
| Sep 30, 2022 | -57.52 Mn |
| Jun 30, 2022 | -54.23 Mn |
| Mar 31, 2022 | -50.75 Mn |
| Dec 31, 2021 | -41.61 Mn |
| Sep 30, 2021 | -39.25 Mn |
| Jun 30, 2021 | -55.40 Mn |
| Mar 31, 2021 | -56.88 Mn |
| Dec 31, 2020 | -65.87 Mn |
| Sep 30, 2020 | 8.99 Mn |
| Jun 30, 2020 | -31.34 Mn |
| Mar 31, 2020 | -46.62 Mn |
| Dec 31, 2019 | -39.42 Mn |
| Sep 30, 2019 | -34.59 Mn |
| Jun 30, 2019 | -35.65 Mn |
| Mar 31, 2019 | -31.26 Mn |
| Dec 31, 2018 | -26.25 Mn |
| Sep 30, 2018 | -16.26 Mn |
| Jun 30, 2018 | -39.66 Mn |
| Mar 31, 2018 | -31.56 Mn |
| Sep 30, 2017 | -26.75 Mn |
| Jun 30, 2017 | -26.12 Mn |
| Mar 31, 2017 | -30.63 Mn |
| Dec 31, 2016 | -38.98 Mn |
| Sep 30, 2016 | -21.17 Mn |
| Jun 30, 2016 | -19.20 Mn |
| Mar 31, 2016 | -17.84 Mn |
| Dec 31, 2015 | -12.37 Mn |
| Sep 30, 2015 | -7.38 Mn |
| Jun 30, 2015 | -10.40 Mn |
| Mar 31, 2015 | -5.16 Mn |